Filtered By:
Source: Journal of Stroke and Cerebrovascular Diseases
Drug: Activase

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 72 results found since Jan 2013.

Comparative analysis of fibrinolytic properties of Alteplase, Tenecteplase and Urokinase in an in vitro clot model of intracerebral haemorrhage
Hematoma lysis with recombinant tissue plasminogen activator (rtPA) has emerged as an alternative therapy for spontaneous intracerebral and intraventricular haemorrhage (ICH and IVH). However, the MISTIE III and CLEAR III trial failed to show significant improvement of favourable outcomes. Besides experimental and clinical trials revealed neurotoxic effects of rtPA. The demand for optimization of fibrinolytic therapy persists. Herein, we used our recently devised clot model of ICH to systematically analyse fibrinolytic properties of rtPA, tenecteplase and urokinase.
Source: Journal of Stroke and Cerebrovascular Diseases - August 15, 2020 Category: Neurology Authors: Naureen Keric, Melanie D öbel, Harald Krenzlin, Elena Kurz, Yasemin Tanyildizi, Axel Heimann, Jochem König, Oliver Kempski, Florian Ringel, Julia Masomi-Bornwassser Source Type: research

Benefits and Safety of Periprocedural Heparin During Thrombectomy in Patients Contra-Indicated for Alteplase
Role of peri-procedural heparin as an adjuvant treatment during mechanical thrombectomy (MT) for patients contra-indicated for alteplase remains a source of debate.
Source: Journal of Stroke and Cerebrovascular Diseases - August 11, 2020 Category: Neurology Authors: Sol ène Hebert, Pierre Clavel, Benjamin Maier, Katsuhiro Mizutani, François Delvoye, Bertrand Lapergue, Malek Ben Maacha, Robert Fahed, Simon Escalard, Jean-Philippe Desilles, Hocine Redjem, Gabriele Ciccio, Stanislas Smajda, Raphael Blanc, Michel Pioti Source Type: research

Visual stroke symptom triage tool to reduce delays due to limited English proficiency in Emergency department stroke activations
Limited English proficiency (LEP) may contribute to delays in care and worse outcomes in patients hospitalized with stroke. Limited access to interpreter services leads to delays in triage, code activation, imaging evaluations, and treatment. At our Comprehensive Stroke Center, 20% of patients with stroke have a Chinese dialect as a primary language and LEP. We sought to assess differences in stroke activation process times and IV alteplase treatment (IVT) rates between English and LEP (Chinese dialect) patients before and after implementation of a visual stroke symptom (VSS) triage tool.
Source: Journal of Stroke and Cerebrovascular Diseases - April 16, 2020 Category: Neurology Authors: Lisa M. Scott Tags: Poster 02 Source Type: research

Utilization of Intravenous Tissue Plasminogen Activator and Reasons for Nonuse in Acute Ischemic Stroke in Saudi Arabia
Background: Recombinant tissue plasminogen activator (rt-PA, alteplase) within 4.5 hours of symptom onset decreases the rate of disability after acute ischemic stroke (AIS). Due to various reasons, alteplase remains underutilized in certain regions ( ∼3% in low- and middle-income countries). Aims: We aimed to estimate the alteplase utilization rate and identify the reasons for nonuse in Saudi Arabia. Methods: We retrospectively reviewed all patients admitted with suspected stroke in the past 24 hours to the stroke unit at King Abdulaziz Medica l City, Riyadh, Saudi Arabia from February 2016 to July 2018.
Source: Journal of Stroke and Cerebrovascular Diseases - March 11, 2020 Category: Neurology Authors: Ali M. Al Khathaami, Bayan Al Bdah, Maisoun Tarawneh, Mohammed Alskaini, Faris Alotaibi, Abdulaziz Alshalan, Mohammed Almuhraj, Daham Aldaham, Nasser Alotaibi Source Type: research

Redefining Early Neurological Improvement After Reperfusion Therapy in Stroke
Background and Purpose: Early neurologic improvement (ENI) in patients treated with alteplase has been shown to correlate with functional outcome. However, the definition of ENI remains controversial and has varied across studies. We hypothesized that ENI defined as a percentage change in the National Institute of Health Stroke Scale (NIHSS) score (percent change NIHSS score) at 24-hours would better correlate with favorable outcomes at 3 months than ENI defined as the change in NIHSS score (delta NIHSS score) at 24 hours.
Source: Journal of Stroke and Cerebrovascular Diseases - December 15, 2019 Category: Neurology Authors: Shashank Agarwal, Shawna Cutting, Brian Mac Grory, Tina Burton, Mahesh Jayaraman, Ryan McTaggart, Michael Reznik, Erica Scher, Andrew D. Chang, Jennifer Frontera, Aaron Lord, Sara Rostanski, Koto Ishida, Jose Torres, Karen Furie, Shadi Yaghi Source Type: research

Safety and Efficacy of Intravenous Thrombolytic Therapy in Patients With Acute Posterior Circulation Stroke: A Single-Center Study
This study was designed to evaluate the prestroke and baseline characteristics, stroke sub-types, complications, and outcomes of PCS patients and compare them with anterior circulation stroke (ACS) after intravenous thrombolysis. Methods: Data of consecutive patients with PCS and ACS treated with alteplase in a standard dose of 0.9 mg/kg in our stroke center were collected and analyzed retrospectively.
Source: Journal of Stroke and Cerebrovascular Diseases - December 1, 2019 Category: Neurology Authors: Xuan Zhu, Nuo Wang, Huangbin Lin, Ping Zhang, Lei Chen, Minmin Zhang, Benqiang Deng, Tao Wu Source Type: research

Even Faster Door-to-Alteplase Times and Associated Outcomes in Acute Ischemic Stroke
We report a single-center, retrospective assessment of the safety and efficacy of alteplase treatment within 45 minutes. Methods: Five hundred and eighty-six patients were treated with alteplase in our emergency departments (EDs) between January 2014 and October 2016; 368 patients were included for analysis.
Source: Journal of Stroke and Cerebrovascular Diseases - October 9, 2019 Category: Neurology Authors: Sarah Jung, Jamie M. Rosini, Jason T. Nomura, Richard J. Caplan, Jonathan Raser-Schramm Source Type: research

Symptomatic Intracerebral Hemorrhage after Intravenous Thrombolysis: Predictive Factors and Validation of Prediction Models
Objective: Thrombolytic therapy with intravenous alteplase (IV-rtPA) has a known risk of symptomatic intracerebral hemorrhage (sICH). We aim to identify factors with a significant association with the development of sICH post-IV-rtPA. We also aim to perform an external validation of sICH predicting scores in our patient population. Material and Methods: We performed a retrospective chart review of patients who received IV-rtPA at our tertiary care hospital. We excluded patients who underwent mechanical thrombectomy.
Source: Journal of Stroke and Cerebrovascular Diseases - September 5, 2019 Category: Neurology Authors: Taha Nisar, Rajanigandhi Hanumanthu, Priyank Khandelwal Source Type: research

Safety and Efficacy of Repeated Thrombolysis with Alteplase in Early Recurrent Ischemic Stroke: A Systematic Review
Background and Aim: The current American Heart Association guidelines for the management of acute ischemic stroke advise against the use of intravenous (IV) alteplase in patients with recurrent stroke occurring within 90 days of their index event. Following these guidelines strictly, patients having early recurrent ischemic stroke would be unable to avail of this reperfusion strategy that has been proven to confer superior clinical outcomes. While some registry-based studies have demonstrated the safety of IV alteplase in this subgroup of patients, data on the repeated use of the drug are lacking.
Source: Journal of Stroke and Cerebrovascular Diseases - July 28, 2019 Category: Neurology Authors: Robert Joseph Cruz Sarmiento, Jose Danilo Bengzon Diestro, Adrian Isidoro Espiritu, Maria Cristina Zarsadias San Jose Source Type: research

Stroke Mimics: An Important Source of Bias in Acute Ischemic Stroke Research
We report the characteristics, frequency, and outcomes of stroke mimics treated at our institution. Using our data, we then explore how the inclusion of stroke mimics in stroke outcomes research may be an important source of bias. Methods: We retrospectively identified all patients treated with alteplase in our emergency department from August 2013 to December 2017 for suspected acute ischemic stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - June 27, 2019 Category: Neurology Authors: Ravi Garg, Megan A. Rech, Michael Schneck Source Type: research

Hemilingual Angioedema after Thrombolysis in a Patient on an Angiotensin II Receptor Blocker
We report a case of a 60-year-old male presenting with hyperacute ischemic stroke developing hemilingual edema after thrombolysis. He was previously maintained on an angiotensin II receptor blocker (ARB), losartan. The swelling resolved over 2 days with immediate administration of intravenous steroids and antihistamine drugs.
Source: Journal of Stroke and Cerebrovascular Diseases - February 13, 2019 Category: Neurology Authors: Jose Danilo Bengzon Diestro, Lady Scarlette Pacsi Sedano, Nikolai Gil Diwa Reyes, Maria Cristina Zarsadias San Jose Tags: Case Report Source Type: research

Efficacy of Tirofiban Administered at Different Time Points after Intravenous Thrombolytic Therapy with Alteplase in Patients with Acute Ischemic Stroke
To evaluate the efficacy of tirofiban administered at different time points within 24 hours of intravenous thrombolysis with alteplase in acute ischemic stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - January 14, 2019 Category: Neurology Authors: Jin Liu, Qiuyan Shi, Yuan Sun, Jingyuan He, Bin Yang, Chunyang Zhang, Rui Guo Source Type: research

Reliability of the Acutely Estimated Premorbid Modified Rankin Scale for Stroke Treatment Decision Making
Background: Premorbid functional status is an important factor in acute stroke treatment decision making. Determining the modified Rankin Score (mRS) accurately may be difficult due to deficits from stroke and lack of collateral information in the acute setting. Data on the reliability of the premorbid mRS in “real-world” practice outside of clinical trial or registry settings are limited. Methods: A retrospective study at a high volume academic primary stroke center. For patients with acute ischemic stroke treated with alteplase between July 2012 and July 2016, hospital electronic records were revie wed for detailed i...
Source: Journal of Stroke and Cerebrovascular Diseases - January 9, 2019 Category: Neurology Authors: WenWen Zhang, Skye Coote, Tanya Frost, Helen M. Dewey, Phillip M. Choi Source Type: research

Isolated Anisocoria as a Presenting Stroke Code Symptom is Unlikely to Result in Alteplase Administration
Acute stroke codes may be activated for anisocoria, but how often these codes lead to a final stroke diagnosis or alteplase treatment is unknown. The purpose of this study was to assess the frequency of anisocoria in stroke codes that ultimately resulted in alteplase administration.
Source: Journal of Stroke and Cerebrovascular Diseases - October 13, 2018 Category: Neurology Authors: Victoria A. Chang, Dawn M. Meyer, Brett C. Meyer Source Type: research

Rectus Sheath Hematoma Following Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Cerebral Infarction: A Case Report
A 76-year-old Japanese man was admitted to our department because of aphasia and right hemiparesis. Brain magnetic resonance imaging showed cerebral infarction caused by occlusion of the left middle cerebral artery, and alteplase therapy was started. Thrombectomy was subsequently performed, resulting in recanalization. On day 4 after admission, he complained of epigastric pain when coughing. On day 8, contrast-enhanced computed tomography showed a left abdominal rectus sheath hematoma without extravasation.
Source: Journal of Stroke and Cerebrovascular Diseases - August 16, 2018 Category: Neurology Authors: Tatsuya Ueno, Takashi Nakamura, Hiroki Hikichi, Akira Arai, Chieko Suzuki, Masahiko Tomiyama Tags: Case Report Source Type: research